Beam Therapeutics (NASDAQ:BEAM) reported an insider sale by Chief Medical Officer Amy Simon on April 1, 2026. According to the company's recent Securities and Exchange Commission filing, Simon sold 6,700 shares at $24.58 per share, producing proceeds of $164,686.
The filing specifies the transaction was an automatic sale to cover tax withholding obligations triggered when restricted stock units vested. The sales were carried out under a Rule 10b5-1 trading plan Simon put in place on May 19, 2023.
Following the disposition, Simon retains direct ownership of 102,735 shares of Beam Therapeutics stock. The equity traded most recently at $24.23, having risen more than 10% over the prior week and delivering a roughly 59% increase compared with the price one year earlier, as noted in the filing.
Market commentary accompanying the filing highlights that InvestingPro analysis views the shares as undervalued at prevailing levels and that analysts maintain a Strong Buy consensus for the company.
Separately, Beam has released clinical updates that have attracted analyst attention. The company announced publication of data from the Phase 1/2 BEACON trial of risto-cel for sickle cell disease. That study enrolled 31 patients and the results were featured in The New England Journal of Medicine, with patient follow-up times spanning from 0.3 to 20.4 months at the most recent data cut-off.
Beam also reported additional findings for BEAM-302 in alpha-1 antitrypsin deficiency (AATD), identifying 60 mg as the pivotal dose for subsequent development. Those clinical updates prompted multiple brokerages to revisit their views and price targets on the stock.
Specifically, Bernstein SocGen Group reiterated an Outperform rating with a $40 price target. Leerink Partners raised its price target to $47 from $42 while keeping an Outperform rating, citing the updated AATD data. William Blair reiterated an Outperform rating and highlighted the highest mean serum AAT level achieved to date. Clear Street maintained a Buy rating with a $37 price target, noting confirmation of the optimal dose for pivotal development in the BEAM-302 program.
These analyst actions followed the clinical disclosures and reflect continued attention to Beam's development programs. For investors seeking more detailed valuation work and financial analysis, the filing references a comprehensive Pro Research Report available for this company and more than 1,400 other U.S. equities.
Summary: An automatic insider sale by Beam's CMO covered tax obligations tied to vested RSUs; the company continues to publish clinical data that has drawn analyst praise and led to maintained or increased price targets.